OPEN ACCESS pISSN 2234-3806
eISSN 2234-3814

Table. 2.

Clinical features of 14 patients with fluconazole non-susceptible bloodstream isolates of Candida albicans

Isolate No. Age (yr)/sex Diagnosis Prior antifungal exposure Immuno-suppression CVC Duration of fungemia (days) Antifungal treatment Patient outcome (days)*
R1 30/F Acute myeloid leukemia Yes (AMB) Yes Yes 5 AMB, ANI Death (6)
R2 63/F Pancreatic cancer No Yes Yes 1 CAS Death (52)
R3 52/M Diabetes mellitus No No No 10 AMB Improved
R4 75/M COPD No No No 3 FLC Death (19)
R5 49/F Breast cancer No No Yes 1 None Death (2)
R6 52/M T/NK-cell lymphoma No No Yes 5 CAS Death (7)
R7 74/M Diabetes mellitus No No Yes 1 None Death (1)
R8 74/F Chronic myeloid leukemia Yes (FLC) Yes No 2 CAS Death (4)
R9 62/M Rheumatoid arthritis No No Yes 4 MICA Improved
R10 79/F Traumatic subdural hemorrhage No No Yes 1 FLC Improved
R11 80/M Spinal abscess No No Yes 2 CAS Improved
D1 79/M Diabetes mellitus Yes (AMB) No Yes 8 FLC Death (15)
D2 43/M Down syndrome No Yes Yes 6 AMB Improved
D3 67/F Fulminant myocarditis, COPD No No Yes 1 None Death (3)

*Time to death after the first positive culture.

Abbreviations: F, female; M, male; COPD, chronic obstructive pulmonary disease; AMB, amphotericin B; FLC, fluconazole; CVC, central venous catheter; ANI, anidulafungin; CAS, caspofungin; MICA, micafungin.

Ann Lab Med 2023;43:614~619 https://doi.org/10.3343/alm.2023.43.6.614

© Ann Lab Med